Ascletis Pharma Inc. (HKG:1672)

Market Cap	6.04B
Revenue (ttm)	1.37M
Net Income (ttm)	-320.25M
Shares Out	961.81M
EPS (ttm)	-0.32
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,957,000
Average Volume	8,956,859
Open	6.20
Previous Close	6.28
Day's Range	5.93 - 6.27
52-Week Range	0.76 - 9.28
Beta	0.36
RSI	49.85
Earnings Date	May 30, 2025

About Ascletis Pharma

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company offers Ritonavir tablet; and ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 231
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1672

Financial Performance

In 2024, Ascletis Pharma's revenue was 1.28 million, a decrease of -97.73% compared to the previous year's 56.60 million. Losses were -300.94 million, 108.0% more than in 2023.

Financial numbers in CNY